FOUND: 14 | Mind Blowing Facts

Shares in European drug companies hit four-month low as Trump tariffs loom

President repeats threat to bring in levies ‘within next week or so’ in attempt to get companies to move production to US

The Guardian - UK · Aug 6, 2025

Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish kroner), missing the consensus of $11.79 billion.

Benzinga · Aug 6, 2025

Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply

Danish company to cut costs and consider layoffs after competition from Mounjaro and the copycat market

The Guardian - UK · Aug 6, 2025

Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign of deeper trouble ahead?

Barchart · Aug 5, 2025

Novo Nordisk Stock Sinks—But Is a Bottom Finally In?

Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings

MarketBeat · Aug 5, 2025

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

Benzinga · Aug 5, 2025

Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

Benzinga · Aug 3, 2025

Benzinga Bulls And Bears: Celestica, Carvana, Novo Nordisk — And Fed Holds Rates Despite Trump Pressure

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Benzinga · Aug 2, 2025

Will Hims & Hers Fall Along With Novo Nordisk?

Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming.

MarketBeat · Aug 1, 2025

Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients

The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S (NYSE:NVO) Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years of age and older with hemophilia A or B without inhibitors.

Benzinga · Aug 1, 2025